Publications
Search our bibliography using the filters on the right-hand side.
Displaying 1 through 9 of 9 publications.
Skip to main content
Krause T, Fleming A, Hurst M, Zema C, Costello J, Hawe E, Ling C. Prognostic factors and surrogate endpoints in obstructive hypertrophic cardiomyopathy: a systematic literature review. Poster presented at the ISPOR Europe 2023; November 14, 2023. Copenhagen, Denmark. [abstract] Value Health. 2023 Dec; 26(12 Supplement):S36. doi: 10.1016/j.jval.2023.09.189
Stull DE, Houghton K, Ainsworth C, Price G, Boye ME. The effects of disease and treatment-associated cancer symptoms on health-related quality-of-life: the mediating effect of fatigue in non-small cell lung cancer and metastatic breast cancer. Poster presented at the 2017 ISPOR 22nd Annual International Meeting; May 22, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A121.
Odom D, Mladsi DM, Purser M, Kaye JA, Palaka E, Charter A, Jensen JA, Sellami D. A matching adjusted indirect comparison of sonidegib and vismodegib in advanced basal cell carcinoma. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 23, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A122.
Guminski A, Stull D, Houghton K, Gutzmer R, Migden MR, Dirix L, Lewis KD, Combemale P, Herd RM, Kudchadkar R, Trefzer U, Sellami D, Lear J, Dummer R. Change in fatigue and correlations with clinical outcome in patients with advanced basal cell carcinoma treated with sonidegib in the BOLT study. Poster presented at the 2016 ISPOR 21st Annual International Meeting; May 24, 2016. Washington, DC. [abstract] Value Health. 2016 May; 19(3):A159.
Stull DE, McBride D, Gnanasakthy A, Balp M. Correlations between changes in the urticaria activity score (UAS7) and the dermatology life quality index (DLQI) from baseline to 28 or 40 weeks: comparisons of trajectories of change in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. [abstract] Value Health. 2013 Nov; 16(7):A509.
Raspa M, Bishop E, Candrilli S, Mitra D, Sacco P, Petrillo J, Bailey D. US caregiver burden in Fragile X syndrome as a function of a health-state utility index. Poster presented at the 2013 ISPOR 16th Annual European Congress; November 2013. Dublin, Ireland. [abstract] Value Health. 2013 Nov; 16(7):A625.
Davis KL, Meyers J, Zhao Z, McCollam P, Murakami M. High-risk vascular disease in Japan: evidence on incidence and prevalence, patient characteristics, and treatment rates from a large Japanese claims database. Poster presented at the 2013 ISPOR 18th Annual International Meeting; April 23, 2013. [abstract] Value Health. 2013 Apr; 16(3):A277.
Davis KL, Mitra D, Yen L. Clinical characteristics, treatment patterns, and resource utilization in a real-world European population with diverticulitis. Poster presented at the 2012 ISPOR 15th Annual European Congress; November 9, 2012. Berlin, Germany. [abstract] Value Health. 2012 Nov; 15(7):A535-6.
Odom D, Devercelli G, Bennett L, Peeters M, Wolf M, Amado R. Health-related quality of life (HRQOL) and colorectal cancer (CRC) symptoms in metastatic CRC: panitumumab plus best supportive care (BSC) versus bsc alone by kras tumor status. Poster presented at the 2008 ISPOR 11th Annual European Congress; November 12, 2008. [abstract] Value Health. 2008 Nov; 11(6):487.